Karyopharm Therapeutics Inc
$ 5.91
8.24%
04 Dec - close price
- Market Cap 93,098,000 USD
- Current Price $ 5.91
- High / Low $ 6.04 / 5.37
- Stock P/E N/A
- Book Value -30.94
- EPS -14.70
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.46 %
- ROE -8.91 %
- 52 Week High 12.45
- 52 Week Low 3.51
About
Karyopharm Therapeutics Inc. is a biopharmaceutical company based in Newton, Massachusetts, that focuses on innovative cancer therapies through its proprietary SINE™ (Selective Inhibitor of Nuclear Export) technology platform. The company’s lead product, Xpovio (selinexor), has garnered multiple regulatory approvals, reflecting its dedication to addressing unmet medical needs in oncology. With a strong drug development pipeline and an emphasis on advancing treatment modalities, Karyopharm is strategically positioned to significantly enhance patient outcomes in cancer care.
Analyst Target Price
$14.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-11 | 2025-05-12 | 2025-02-19 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-04 | 2023-02-15 |
| Reported EPS | -3.82 | -4.07 | -2.77 | -3.6 | -3.9 | 0.15 | -0.32 | -0.36 | -0.3 | -0.29 | -0.3 | -0.43 |
| Estimated EPS | -2.21 | -3.91 | -3.09 | -4.03 | -3.92 | -0.3 | -0.33 | -0.31 | -0.28 | -0.34 | -0.37 | -0.35 |
| Surprise | -1.61 | -0.16 | 0.32 | 0.43 | 0.02 | 0.45 | 0.01 | -0.05 | -0.02 | 0.05 | 0.07 | -0.08 |
| Surprise Percentage | -72.8507% | -4.0921% | 10.356% | 10.67% | 0.5102% | 150% | 3.0303% | -16.129% | -7.1429% | 14.7059% | 18.9189% | -22.8571% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KPTI
2025-11-03 04:51:05
This study investigates the therapeutic potential of selinexor (KPT-330), an Exportin-1 (XPO1) inhibitor, against anaplastic thyroid carcinoma (ATC), a highly lethal malignancy. Researchers found that selinexor significantly reduced ATC cell growth and induced apoptosis both in vitro and in vivo. The combination of selinexor with doxorubicin also demonstrated synergistic growth inhibition in ATC cells, suggesting a promising new treatment approach for ATC patients.
2025-10-16 04:00:00
Karyopharm Therapeutics (KPTI) reported that its EVP, CFO & Treasurer, Lori Macomber, received 43,650 restricted stock units (RSUs) on October 15, 2025, at a price of $0. These RSUs will vest 100% on December 31, 2026, and convert into common stock on a one-for-one basis. After this award, Macomber's beneficial ownership stands at 54,316 shares, reflecting a one-for-fifteen reverse stock split effected on February 25, 2025.
2025-10-16 04:00:00
Karyopharm Therapeutics (KPTI) reported that its EVP, Chief Development Officer Stuart Poulton, received 39,682 restricted stock units (RSUs) on October 15, 2025, under the company’s 2022 Equity Incentive Plan at a price of $0. These RSUs will vest 100% on December 31, 2026, and convert to common stock on a one-for-one basis. Following this grant, Poulton's direct beneficial ownership in the company stands at 67,392 shares.
2025-10-16 04:00:00
Karyopharm Therapeutics (KPTI) CEO Richard Paulson was awarded 114,285 restricted stock units (RSUs) on October 15, 2025, with a grant price of $0. These RSUs will vest 100% on December 31, 2026, and convert into common stock on a one-for-one basis. Following this award, Paulson's beneficial ownership in the company stands at 198,331 common shares.
2025-10-16 04:00:00
Karyopharm Therapeutics (KPTI) reported on a Form 4 that EVP & Chief Commercial Officer Sohanya Cheng received 43,650 Restricted Stock Units (RSUs) on October 15, 2025, at a price of $0. These RSUs will convert to common stock on a one-for-one basis and vest 100% on December 31, 2026. Following this award, Ms. Cheng beneficially owns 79,506 shares directly.
2025-10-16 04:00:00
Karyopharm Therapeutics (KPTI) reported that Michael Mano, SVP, General Counsel & Secretary, received 43,650 restricted stock units (RSUs) on October 15, 2025. These RSUs convert to common stock and vest 100% on December 31, 2026. Following this grant, Michael Mano beneficially owned 65,075 shares directly.
